Form 4 Enovis Corp For: 1 October By Investing.com
This article from Investing.com announces the publication of a Form 4 for Enovis Corp for October 1st. It provides various financial market data, including indices, commodities, and share prices, alongside news and analysis articles from Investing.com. The core content is the announcement of the Form 4 filing.
Enovis Corporation (ENOV) stock price, news, quote and history
Enovis Corporation (ENOV) stock is currently trading at $18.19, down 1.49%, with key financial metrics including a market cap of $1.049 billion and an EPS of -19.27. The medical technology company, which operates in Prevention and Recovery and Reconstructive segments, has shown significant declines in its stock performance over various periods, including a 40.06% drop over the last year. Analysts have an average target price of $38.33, with the latest rating from Wells Fargo maintaining an "Overweight" status but lowering the price target to $33.
Enovis Corporation (ENOV) stock price, news, quote and history
This Yahoo Finance article provides a comprehensive overview of Enovis Corporation (ENOV), a medical technology company. It includes current stock price, historical performance data, key financial statistics, company profile, recent news, and analyst insights. The company specializes in developing clinically differentiated solutions across its Prevention and Recovery and Reconstructive segments.
Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
Enovis has become the first industry partner to sponsor multiple registries within the American Academy of Orthopaedic Surgeons (AAOS) Registry Program. In addition to its long-standing support of the American Joint Replacement Registry (AJRR), Enovis will now also sponsor the Shoulder & Elbow Registry (SER) through 2027. This expanded partnership aims to enhance data collection, improve data quality, and strengthen orthopaedic registries as resources for clinicians to improve patient care, particularly in shoulder and elbow conditions.
Enovis expands support to AAOS Shoulder & Elbow Registry, enhancing data on shoulder and elbow care.
Enovis has expanded its support to the American Academy of Orthopaedic Surgeons' Shoulder & Elbow Registry through 2027, aiming to improve data collection and understanding of shoulder and elbow treatments. This move extends their previous sponsorship with the American Joint Replacement Registry. The enhanced data will help clinicians refine treatment outcomes and advance patient care, demonstrating Enovis' commitment to evidence-based innovation in orthopedics.
Enovis CORP (ENOV) insider adds 2,660 shares in open-market buy
Enovis CORP's Chief Administrative Officer, Oliver Engert, recently purchased 2,660 shares of common stock on the open market at a weighted average price of $18.80 per share. This transaction, which occurred on September 4, 2026, increased his direct holdings to 63,898 shares. The individual trades ranged from $18.74 to $18.85 per share.
Enovis stock hits 52-week low at 18.17 USD
Enovis Corporation's stock has reached a 52-week low of $18.17, trading below InvestingPro's Fair Value estimate, which suggests it may be undervalued. Despite a 42.24% decline over the past year and not being profitable in the last twelve months, analysts predict a return to profitability this year. The company recently reported better-than-expected Q2 2026 earnings but faces cautious investor sentiment due to cost pressures and the acquisition of eCential Robotics for approximately €176 million, which led BMO Capital and Citizens to lower their price targets.
Enovis stock hits 52-week low at 18.17 USD
Enovis Corporation's stock has hit a 52-week low of $18.17, trading below InvestingPro's Fair Value estimate and reflecting a 42.24% decline over the past year. Despite not being profitable in the last twelve months, analysts predict a return to profitability this year. The company recently reported strong Q2 2026 adjusted earnings and acquired eCential Robotics for approximately €176 million, although these developments have led to cautious investor sentiment and lowered price targets from BMO Capital and Citizens due to margin concerns.
Enovis CAO Oliver Engert buys $50,008 in company stock
Oliver Engert, Chief Administrative Officer at Enovis Corp. (NYSE: ENOV), recently purchased 2,660 shares of the company's common stock for a total of $50,008. This insider purchase occurs as Enovis stock trades near its 52-week low and is considered undervalued by InvestingPro analysis. The company recently reported strong Q2 2026 earnings and acquired eCential Robotics, though analysts have adjusted price targets due to potential margin headwinds.
Enovis Corp Lobbying Profile, 2024
This OpenSecrets profile details the lobbying activities of Enovis Corp for 2024. It indicates that the company, categorized under Pharmaceuticals/Health Products, spent $130,000 on federal lobbying, all of which was direct spending, with no subsidiaries involved. The data, updated on July 23, 2026, covers spending from January 1 to June 30 of that year.
Enovis to acquire surgical tech provider eCential Robotics for $180M
Enovis Corp., a medical technology company, announced its binding offer to acquire eCential Robotics for €155 million (over $180 million USD). This acquisition will integrate eCential's modular surgical robotics platform into Enovis' ASTRA technology platform, enhancing its offerings in orthopedics, particularly in spine and knee surgeries, with future plans to expand into shoulder procedures. Enovis aims to bring a new robotic platform to market within two years, leveraging eCential's expertise, IP, and talent.
Enovis CORP CEO McDonald Damien Acquires 13,035 Shares at $19.15 on September 4, 2026
Enovis CORP CEO McDonald Damien acquired 13,035 shares of the company stock on September 4, 2026, at a price of $19.15 per share. This transaction increased his total holdings to 247,077 shares. The article highlights this insider purchase as a key event for investors to consider regarding the CEO's stake in Enovis CORP.
Enovis CAO Oliver Engert buys $149,970 in company stock
Enovis Chief Administrative Officer Oliver Engert recently purchased $149,970 worth of company stock, acquiring shares at weighted average prices of $20.32 and $19.46. This insider buying occurred after a 25% stock decline, with the stock trading near its 52-week low. The company also reported strong Q2 2026 earnings and announced the acquisition of eCential Robotics for approximately €176 million, though analysts have lowered price targets due to potential margin headwinds from the acquisition.
Enovis CEO McDonald buys $249,620 in Enov shares
Enovis CEO Damien McDonald recently purchased 13,035 shares of Enovis common stock for approximately $249,620, increasing his direct holdings to 247,077 shares. This transaction occurred while the stock was trading near its 52-week low following a 25% decline. InvestingPro analysis suggests the stock is undervalued with significant upside potential.
Citizens JMP Maintains Enovis Corp(ENOV.US) With Buy Rating, Cuts Target Price to $47
Citizens JMP has reiterated its Buy rating for Enovis Corp (ENOV.US) but has lowered its target price to $47. This adjustment suggests a continued positive outlook on the company despite a revised valuation.
Enovis Is Maintained at Buy by Freedom Capital Markets
Freedom Capital Markets has reiterated its Buy rating on Enovis. This indicates continued confidence in the company's stock performance from the analyst firm.
Enovis stock hits 52-week low at 19.12 USD By Investing.com
Enovis Corporation's stock has fallen to a new 52-week low of $19.12, marking a significant decline of 18.65% in the past week and 39.14% over the past year. Despite the downturn, InvestingPro Tips suggest the stock is oversold and potentially undervalued, with analysts predicting a return to profitability this year. The company recently reported strong Q2 2026 earnings, beating estimates, and acquired eCential Robotics, though analysts have adjusted price targets due to short-term outlook and cost pressures.
Enovis (NYSE: ENOV) executive buys 7,598 shares outside 10b5-1 plan
Enovis Chief Administrative Officer Oliver Engert purchased 7,598 shares of the company's common stock through open market transactions on September 2 and 3, 2026. The purchases were made at weighted average prices of $20.32 and $19.46 per share, respectively, and were not conducted under a 10b5-1 trading plan. Following these transactions, Engert directly holds 61,238 shares of Enovis common stock.
Enovis Boosts Surgical Robotics Portfolio With eCential Acquisition
Enovis Corporation is acquiring France-based eCential Robotics for an upfront enterprise value of 155 million euros, with up to 35 million euros in milestone-based payments. This acquisition aims to enhance Enovis's surgical robotics portfolio by integrating eCential's modular robotic platform with Enovis's existing ASTRA and ARVIS systems. Despite an initial dip in Enovis's stock and a projected short-term impact on adjusted EBITDA margins, the deal is expected to strengthen Enovis's long-term position in the rapidly growing orthopedic robotics market.
Enovis (NYSE: ENOV) CEO adds 13,035 shares in open-market buy
Enovis Corp's CEO, Damien McDonald, purchased 13,035 shares of common stock on September 4, 2026, in an open-market transaction. The shares were acquired at a weighted average price of $19.15, increasing his direct holdings to 247,077 shares. This transaction was not conducted under a Rule 10b5-1 trading plan.
Enovis inks eCential takeover to develop surgical ortho robots
Enovis is acquiring eCential Robotics for an upfront payment of 155 million euros, with an additional 35 million euros in contingent payments tied to development milestones. This acquisition aims to significantly advance Enovis's surgical robotics capabilities, particularly for orthopedic procedures. The company plans to launch a knee robot in late 2028 and a shoulder robot in 2029, leveraging eCential's proven technology and existing collaborations.
Citizens lowers Enovis stock price target on robotics acquisition
Citizens has lowered its price target for Enovis Corp (NYSE:ENOV) to $47 from $55, while maintaining a Market Outperform rating, following the company's acquisition of eCential Robotics for approximately $205 million. This acquisition aims to create a comprehensive enabling technology ecosystem for surgical robotics, with the first robotic launch expected in late 2028. Despite the stock struggling recently and the lowered price target, InvestingPro analysis suggests Enovis is undervalued at current levels, and analysts maintain a Buy consensus.
Enovis Targets Robotic Surgery Expansion With €155M eCential Robotics Deal
Enovis (NYSE: ENOV) has made a binding offer to acquire eCential Robotics for €155 million, with up to €35 million in milestone payments, aiming to expand its robotic surgery capabilities. The acquisition is expected to close by the end of 2026 and will integrate eCential's technology into Enovis' ASTRA ecosystem, with plans to launch new robotic platforms for total knee and shoulder procedures. While the deal is projected to cause temporary dilution in adjusted EBITDA margins and an increase in leverage, Enovis expects long-term benefits from robotics sales and reaffirmed its free cash flow targets.
Enovis to acquire eCential Robotics for up to €190 million
Enovis Corporation has announced a binding offer to acquire eCential Robotics, a French surgical robotics developer, for an upfront enterprise value of €155 million, with potential additional payments of €35 million. The acquisition, expected to close by year-end 2026, will integrate eCential Robotics' modular platform into Enovis' ASTRA technology and establish a new robotics center in Grenoble, France. Enovis anticipates a short-term dilution to its adjusted EBITDA margin in 2027 but projects a return to year-over-year margin improvement and increased free cash flow conversion by 2028.
Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
Enovis Corporation (NYSE: ENOV), a medical technology company, announced its participation in the 2026 Wells Fargo Healthcare Conference. CEO Damien McDonald and CFO Ben Berry will host a fireside chat on September 8, 2026, at 1:30 p.m. ET. A live audio webcast and replay will be available on the company's investor relations website.
Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
Enovis Corporation announced its participation in the 2026 Wells Fargo Healthcare Conference. The innovation-driven medical technology growth company is scheduled to attend the conference on Tuesday, September 8, 2026, at the Encore Boston Harbor. This syndicated content was distributed via GlobeNewswire.
Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
Enovis Corporation announced its participation in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026. CEO Damien McDonald and CFO Ben Berry will host a fireside chat at 1:30 p.m. Eastern Time. A live audio webcast and replay will be available on the company's investor relations website.
William Blair Maintains Enovis Corp(ENOV.US) With Buy Rating
William Blair has reaffirmed its Buy rating on Enovis Corp (ENOV.US). This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
Enovis (ENOV) surpassed Q2 earnings and revenue estimates, reporting $0.90 per share against a Zacks Consensus Estimate of $0.83, and revenues of $582.78 million, exceeding expectations by 0.15%. The company has consistently beaten EPS estimates over the last four quarters. Despite the positive results, the stock currently holds a Zacks Rank #3 (Hold), suggesting it will perform in line with the market.
First National Bank of Omaha Makes New Investment in Enovis Corporation $ENOV
First National Bank of Omaha has made a new investment in Enovis Corporation, purchasing 60,369 shares valued at approximately $1.25 million during the second quarter. This move makes First National Bank of Omaha an approximate 0.10% owner of Enovis. Other institutional investors like Dimensional Fund Advisors LP and Rubric Capital Management LP also adjusted their positions in the company, highlighting significant institutional interest.
What Enovis (ENOV)'s Narrowing Losses And Reaffirmed 2026 Outlook Means For Shareholders
Enovis Corporation reported Q2 2026 results with reduced net losses and reaffirmed its 2026 revenue guidance of US$2.31 billion to US$2.37 billion, including 4–6% organic growth. This indicates management's confidence in the company's trajectory, despite ongoing losses. The investment narrative emphasizes consistent profitability from its medtech portfolio, with margin improvement and successful integration of acquisitions being key near-term catalysts and risks.
What Enovis (ENOV)'s Narrowing Losses And Reaffirmed 2026 Outlook Means For Shareholders
Enovis Corporation reported narrowing losses and reaffirmed its 2026 revenue guidance of US$2.31 billion to US$2.37 billion, including 4–6% organic growth. This supports the investment narrative that execution on margin improvement is a key near-term catalyst, despite ongoing integration complexities and historical losses. The article emphasizes that while losses are improving, the company's long-term profitability and fair value will depend on how effectively guided growth translates into better margins.
Enovis Corporation (NYSE:ENOV) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Enovis Corporation (NYSE:ENOV) has received a "Moderate Buy" consensus rating from analysts, with eight out of ten recommending a buy, one a hold, and one a sell. The average 12-month price target is $41.29, significantly higher than its current share price of $24.79. Recent quarterly results surpassed expectations, and insiders have purchased additional shares, indicating confidence in the company.
Canaccord Genuity Group Lowers Enovis (NYSE:ENOV) Price Target to $45.00
Canaccord Genuity Group has lowered its price target for Enovis (NYSE:ENOV) to $45.00 from $50.00, while reiterating a "buy" rating, indicating a potential 72.53% upside. This adjustment follows other analyst updates, though the stock maintains an overall "Moderate Buy" rating with an average target of $41.29. Enovis recently surpassed quarterly earnings expectations and provided strong fiscal 2026 EPS guidance, with significant institutional ownership and recent insider share purchases highlighting investor interest.
Rubric Capital discloses 3.9M-share Enovis (ENOV) position in Schedule 13G
Rubric Capital Management LP and David Rosen have jointly filed a Schedule 13G, disclosing beneficial ownership of 3,900,000 shares of Enovis Corporation (ENOV) common stock. This position represents 6.78% of the company's outstanding shares, based on 57,562,603 shares as of May 1, 2026. Both parties report shared voting and dispositive power over these shares, which are held by investment funds advised by Rubric Capital, including Rubric Capital Master Fund LP.
Enovis Corporation (ENOV) Stock Forecasts
Argus has lowered its target price for Enovis Corporation (ENOV) to $23.00. Enovis is a medical technology company providing devices and services for patient care, from injury prevention to rehabilitation. The current price of ENOV stock is $26.25.
BMO Capital Maintains Enovis Corp(ENOV.US) With Buy Rating, Raises Target Price to $30
BMO Capital has reiterated its Buy rating for Enovis Corp (ENOV.US) and increased its target price to $30. This update indicates a positive outlook from the firm regarding Enovis's financial performance and future prospects.
Can Enovis (ENOV) Narrowing Losses Without Strong Sales Growth Sustain Its Long-Term Strategy?
Enovis Corporation (ENOV) reported Q2 2026 sales of US$582.78 million, a modest increase year-over-year, and significantly reduced its net loss to US$1.19 million from US$36.74 million. The company reaffirmed its 2026 revenue guidance of US$2.31 billion to US$2.37 billion, indicating management's confidence despite only incremental sales growth. The article explores whether Enovis's strategy of narrowing losses without robust sales growth, primarily through acquisitions in medtech and orthopedics, is sustainable for long-term profitability.
Can Enovis (ENOV) Narrowing Losses Without Strong Sales Growth Sustain Its Long-Term Strategy?
Enovis (ENOV) reported modestly higher sales in Q2 2026, reaching US$582.78 million, while significantly reducing its net loss to US$1.19 million. The company reaffirmed its 2026 revenue outlook of US$2.31 billion to US$2.37 billion, indicating confidence despite incremental sales growth. The article discusses whether Enovis's strategy of narrowing losses without substantial sales growth is sustainable, given its history of acquisitions, concentration in orthopedics, and potential delays in technology launches.
Enovis earnings up next as analysts eye Lima deal, cash flow
Enovis Corp. is preparing to report its second-quarter earnings, with analysts focusing on the company's integration of the Lima acquisition and its free cash flow generation. While EPS estimates have slightly decreased, Wall Street maintains a bullish outlook on the stock, with a consensus price target suggesting a significant upside. Investors will be scrutinizing margin performance and the company's ability to capitalize on market tailwinds in the orthopedic devices sector.
Enovis Corporation (ENOV) Stock Forecasts
Argus has raised its target price for Enovis Corporation (ENOV) to $32.00, with the stock currently trading at $25.13. Enovis Corp is a medical technology company specializing in devices and services for patient care, from injury prevention to rehabilitation. Full details are available in an exclusive report for Yahoo Finance Silver subscribers.
Enovis (ENOV) Reaffirmed Guidance And Improved Margins, Is The Stock Still Undervalued?
Enovis (ENOV) reaffirmed its full-year 2026 revenue guidance and reported improved Q2 results, including organic growth and margin improvement, leading to a smaller net loss. Despite recent stock performance showing some momentum, the company is still considered undervalued by analysts, trading below the fair value estimate of $42.30. The article highlights both growth opportunities in the orthopedic market and integration risks from acquisitions, advising investors to review the underlying data.
Should You Investigate Enovis Corporation (NYSE:ENOV) At US$26.61?
This article evaluates Enovis Corporation's (NYSE:ENOV) stock at its current price of US$26.61. It will likely delve into financial metrics, analyst sentiment, and market conditions to determine if it's an attractive investment opportunity.
Enovis Q2 Earnings Call Highlights
Enovis reported Q2 2026 sales of $583 million, a 3% increase, driven by growth in its Reconstruction business despite challenges from the Middle East conflict and inflation. The company reaffirmed its full-year guidance, expecting sales growth to accelerate in Q4 with new product launches. Despite cost pressures, Enovis saw improved margins and positive free cash flow, and aims to further reduce leverage and expand margins in the long term.
Evercore Maintains Enovis Corp(ENOV.US) With Buy Rating, Maintains Target Price $32
Evercore has reiterated its Buy rating on Enovis Corp (ENOV.US) and maintained its target price at $32. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Enovis Q2 Earnings Call Highlights
Enovis reported Q2 2026 sales of $583 million, up 3% reported and 5% organically, driven by strong growth in its Reconstruction business. The company reaffirmed its full-year guidance, expecting sales growth to accelerate in Q4 due to new product launches and market improvements, despite headwinds from Middle East disruptions and inflation. Enovis also saw improved margins and positive free cash flow in the first half, while reducing leverage.
Enovis (ENOV) Stock Eyes Margin Gains as Free Cash Flow Improves
Enovis (ENOV) stock saw a modest 1.1% increase despite reporting significant improvements in its Q2 financials, including a narrowed net loss, improved gross and EBITDA margins, and positive free cash flow of US$31 million. The company's future prospects hinge on translating operational progress into sustained free cash flow and margin strength, though skeptics highlight execution risks and inflationary pressures. Investors are focusing on how Enovis's current financial profile aligns with its long-term profitability goals and debt reduction efforts.
Enovis Corporation Stock 12‑Month Price Target Cut to $41.25, Implies 37% Upside
The average 12-month price target for Enovis Corporation (ENOV) stock has been lowered from $41.58 to $41.25 by analysts, despite this reduction, the new target still suggests a potential upside of approximately 37% based on the August 5th closing price. The consensus rating for ENOV remains "Buy" among 13 analysts, with 12 recommending a Buy and 1 a Hold.
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates
Enovis (ENOV) reported Q2 earnings of $0.9 per share, exceeding the Zacks Consensus Estimate of $0.83, and revenues of $582.78 million, also surpassing estimates. The company has consistently beaten EPS estimates over the last four quarters and revenue estimates three out of the last four quarters. Despite outperforming the market year-to-date, Enovis currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.
Enovis Q2 2026 slides show margin gains despite stock decline
Enovis Corporation reported strong second-quarter 2026 results, showing 5% organic growth, significant margin expansion, and improved free cash flow. Despite beating earnings expectations and reaffirming full-year guidance, the stock declined 8.4%, reflecting investor concerns about near-term headwinds and the absence of raised guidance. The company emphasized continued execution, new product launches like the ARVIS surgical system, and a focus on profitability improvement, targeting high-teens EBITDA margins.
